Reach Us +44-1202068036
ENESTgoal: Evaluation Of Treatment-Free Remission (TFR) In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) And Sustained Deep Molecular Response (MR) Following Switch To Nilotinib | 19901
ISSN: 2155-9864

Journal of Blood Disorders & Transfusion
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

ENESTgoal: Evaluation of Treatment-Free Remission (TFR) in patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and sustained deep Molecular Response (MR) following switch to nilotinib

2nd International Conference on Hematology & Blood Disorders

Andrea Magley, Eric J Feldman, Michae W Deininger, Jerald Radich, Christopher Keir, Felice Lin and Michael Mauro

Posters: J Blood Disorders Transf

DOI: 10.4172/2155-9864.S1.007

Sustained TFR has been reported in clinical trials ofpatients withCML-CP who achievedsustaineddeep MR on imatinib therapy. Nilotinib treatmentresults in high rates of sustained deep MR, a key eligibility criterion for TFR studies.The randomized, phase 2 ENESTgoal study(NCT01744665) will evaluate TFR among patients with CML-CP who achievesustained MR4.5 (BCR-ABL≤0.0032% on the International Scale [IS] by real-timequantitative polymerase chain reaction [RQ- PCR]) after switching tonilotinib.ENESTgoal will enrollapproximately 300 patients with major molecular response (BCR- ABLIS≤0.1%)but with detectable disease (BCR-ABLIS>0.0032%), as assessed by a central laboratory, after ≥1 year ofimatinib therapy. Patients will switch to nilotinib 300 mg twice dailyonstudy entry andbe monitored quarterly for up to 2 years; those who achieveconfirmed MR4.5 during the monitoring phase will be randomized to enter a 1- or 2-year consolidation phaseof continuednilotinib treatment. Patients will then stop nilotinib therapy and enter the 3-year TFR phase if MR4.5is maintained throughout the consolidation phase. RQ-PCR assessments will be performed monthly for the first 6 months of the TFR phase, then every 2 months for 18 months and then quarterlythereafter. Patients with molecular relapse, defined in ENESTgoalas confirmed loss of MR4 (or BCR-ABLIS>0.01%), will re-initiate nilotinibtherapy. The primary endpoint of the study is the molecular relapse-free rate at 6 months after suspension of nilotinib therapy. ENESTgoal is currently open for enrollment in the United States.
Relevant Topics